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June 14, 2011:2454–60patient. A CAC-based reclassification has implications for
preventive therapy strategies for patients at intermediate cardiac
risk that need to be tested in a prospective, randomized manner
(4,5).
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Reply
We agree with the comments of Dr. McEvoy and colleagues
regarding our paper (1) that there is an urge to implement coronary
artery calcium (CAC) cutoff scores in clinical practice to enhance
cardiovascular risk stratification in the individual patient. This
especially pertains to persons at intermediate cardiovascular risk, in
whom risk management strategies are least clear. Yet, we do not
think that reporting the absolute CAC score reclassification cutoffs
we would have found by using the classic Framingham Risk Score
instead of our Framingham “refitted” model would be helpful. The
Framingham Risk Score is designed for a population 30 to 74 years
of age (2). Our study focuses on the elderly, of whom a substantial
proportion is older than 75 years of age. Previous research within
the Rotterdam study has pointed out that the Framingham Risk
Score does not fit well in our population (3). Thus, cutoffs derived
in our cohort using the Framingham Risk Score would not be
meaningful.
Of course, in a utopia we would be able to overcome the
inaccuracy of available “general” risk functions. However, we think
it would be helpful to create more tailored risk functions for
populations with specific demographics and/ or presence of car-
diovascular symptoms. Empirically derived cutoffs from these
populations are more likely to apply to the individual patient,
although they should be tested in comparable study populationsbefore they can be safely used in clinical practice. So, despite the
urgent need for CAC cutoffs in cardiovascular risk stratification of
the individual patient, we feel that abundant research still has to be
performed before CAC cutoff scores can safely be used in clinical
practice.
*Suzette E. Elias-Smale, MD
Jacqueline C. M. Witteman, PhD
*Department of Epidemiology
Erasmus Medical Center
P.O. Box 2040
Rotterdam, Zuid-Holland 3000 DR
the Netherlands
E-mail: s.elias@erasmusmc.nl
doi:10.1016/j.jacc.2011.02.031
EFERENCES
1. Elias-Smale SE, Proenca RV, Koller MT, et al. Coronary calcium score
improves classification of coronary heart disease risk in the elderly: the
Rotterdam study. J Am Coll Cardiol 2010;56:1407–14.
2. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H,
Kannel WB. Prediction of coronary heart disease using risk factor
categories. Circulation 1998;97:1837–47.
3. Koller MT, Steyerberg EW, Wolbers M, et al. Validity of the
Framingham point scores in the elderly: results from the Rotterdam
study. Am Heart J 2007;154:87–93.
Nonrandomized Data on
Drug-Eluting Stents Compared
With Coronary Bypass Surgery
Caution With Interpretation
In a recent issue of the Journal, Park et al. (1) presented
long-term follow-up results from the Asan-Multivessel Registry
in which patients are followed after percutaneous coronary
intervention (PCI) with drug-eluting stents (DES) or coronary
artery bypass grafting (CABG) for the treatment of multivessel
coronary artery disease. After 5 years, similar rates of death or
the composite endpoint of death, myocardial infarction, or
stroke were found in the DES and CABG groups. This is the
first paper to compare these groups after such long follow-up,
but it should be highlighted that this is a nonrandomized study.
To date, only the SYNTAX (Synergy Between PCI With
TAXUS and Cardiac Surgery) trial compared patients random-
ized to DES or CABG and after 1 year already showed that
DES failed to reach noninferiority to CABG (2). A possible
explanation for the contradicting results of Park et al. (1) is that
apart from baseline characteristics (age, sex, body mass index)
and comorbid conditions (hypertension, hyperlipidemia, diabe-
tes requiring insulin, heart failure, prior myocardial infarction),
the severity of multivessel disease is less worse than in the
SYNTAX trial (Table 1), with an overall SYNTAX coronary
score that is much lower in the DES group (SYNTAX trial
28.4% vs. 17.4% in the present study). The SYNTAX trial also
included more than twice as many patients with a left main
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prognosis (3). Furthermore, CABG has always shown a better
prognosis in patients with more extensive coronary artery
disease. Outcomes in the study by Parks et al. (1), therefore,
represent results from a patient cohort in whom it is unlikely
that an advantage of surgery could be demonstrated.
To conclude, the recently published results show interesting
data on patients treated with DES in perspective to CABG in
a real-world design, but this should not lead to treatment
preferences for patients with multivessel coronary artery disease.
SYNTAX remains the only randomized trial addressing this issue,
and although we anticipate the stronger long-term results from
this trial, conclusions from the Asan-Multivessel Registry can only
be drawn with caution.
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Baseline Characteristics ComparisonTable 1 Baseline Characteristics Comparison
SYNTAX
(n  1,800)
Asan Registry
(n  3,042)
DES CABG DES CABG
Age, yrs* 65.2 65.0 62.0 61.8
Male, %* 76.4 78.9 69.4 73.2
Mean body mass index, kg/cm2* 28.1 27.9 25.1 24.8
Current smoker, %† 18.5 22.0 29.5 33.6
Hypertension, %* 68.9 64.0 57.1 47.9
Hyperlipidemia, %* 78.7 77.2 24.1 31.7
Medically treated diabetes
Any, %† 25.6 24.6 31.6 26.9
Requiring insulin, %* 9.9 10.4 5.6 5.1
Ejection fraction 30%, % 1.3 2.5 0.9 3.3
Congestive heart failure, %* 4.0 5.3 1.4 4.5
Prior myocardial infarction, %* 31.9 33.8 10.1 19.7
Left main lesion, %* 39.5 38.8 11.5 24.9
Total occlusion, % 24.2 22.2 7.1 43.9
SYNTAX score, %* 28.4 29.1 17.4 29.9
*Higher risk profile patients in SYNTAX (Synergy Between PCI With TAXUS and Cardiac Surgery).
†Higher risk profile patients in Asan-Multivessel Registry.
CABG  coronary artery bypass grafting; DES  drug-eluting stent(s).artery disease. N Engl J Med 2009;360:961–72.3. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass
graft surgery on survival: overview of 10-year results from randomised
trials by the Coronary Artery Bypass Graft Surgery Trialists Collabo-
ration (erratum in Lancet 1994;344:1446). Lancet 1994;344:563–70.
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We thank Dr. Head and colleagues for their remarks concerning
our paper (1). Although a randomized clinical trial (RCT) is the
ideal method for measuring true treatment effects, the RCT does
not necessarily provide the final answer to treatment effectiveness,
as there are many restrictions that limit generalizability of study
findings (2).
There are many considerations when one is choosing a treat-
ment strategy for coronary revascularization (3). In real practice, it
is mostly likely that patients with less complex anatomy of
atherosclerotic coronary artery disease (CAD) and less comorbidity
tend to be more often referred for percutaneous coronary inter-
vention (PCI), whereas those with more severe anatomic complex-
ity and coexisting conditions tend to be preferentially considered
for coronary artery bypass grafting (CABG). These factors, there-
fore, may cause potential bias due to confounding by indication in
comparative clinical strategies studies (4).
Several comparisons of CABG with PCI suggest a strong
relation between the extent of coronary disease and the relative
effectiveness of these procedures on survival (5,6). In particular,
clinical registry studies have reported that patients with the least
extensive coronary disease (i.e., 2-vessel disease) have better
survival after PCI, whereas patients with the most extensive disease
(i.e., 3-vessel disease) have better survival after CABG. Our
registry data collected consecutive “real world” patients who
received multivessel revascularization with minimal exclusion cri-
teria. Therefore, the major difference in patient inclusion of our
study and the SYNTAX (Synergy Between PCI With TAXUS
and Cardiac Surgery) trial was the enrollment of patients with
2-vessel disease. A more beneficial effect of PCI with drug-eluting
stents relative to CABG for patients with less severe, 2-vessel
disease is the most likely explanation for our contradicting results
compared with the SYNTAX trial. Referring patients with
2-vessel disease for CABG is common in clinical situations, but
this subset was not included in the SYNTAX trial.
Although findings of observational studies should be interpreted
with caution due to selection bias and unmeasured, multiple
confounders, well-conducted observational studies can address
long-term effectiveness and safety problems of revascularization
procedures in a broader array of patients by the optimal judgment
of the treating physician in routine practice, and may more
accurately reflect “real world” experience.
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